Orelabrutinib (ICP-022)

orelabutinib · Beijing InnoCare Pharma Tech Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Orelabrutinib (ICP-022), covering 2023-04-18 to 2023-04-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]

See pricing